The Association between Cannabis Product Characteristics and Symptom Relief Sarah S. STITH, Jacob M. VIGIL, Franco BROCKELMAN, Keenan KEELING, Branden HALL Scientific Reports - Nature, 2019, 9, 2712. Published online 2019 Feb 25. doi: 10.1038/s41598-019-39462-1 PMCID: PMC6389973 PMID: 30804402 Abstract Federal barriers and logistical challenges have hindered measurement of the real time effects from the types of cannabis products used medically by millions of patients in vivo. Between 06/06/2016 and 03/05/2018, 3,341 people completed 19,910 self- administrated cannabis sessions using the mobile device software, ReleafApp to record: type of cannabis product (dried whole natural Cannabis flower, concentrate, edible, tincture, topical), combustion method (joint, pipe, vaporization), Cannabis [...]
Lire la suiteClinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]
Lire la suiteA protocol for the delivery of cannabidiol (CBD) and combined CBD and ∆9-tetrahydrocannabinol (THC) by vaporisation Nadia SOLOWIJ, Samantha J. BROYD, Hendrika H. Van HELL, Arno HAZEKAMP BMC Pharmacol Toxicol, 2014, 15, 58 Published online 2014 Oct 16. doi: 10.1186/2050-6511-15-58 PMCID: PMC4274767 PMID: 25319497 Abstract Background Significant interest has emerged in the therapeutic and interactive effects of different cannabinoids. Cannabidiol (CBD) has been shown to have anxiolytic and antipsychotic effects with high doses administered orally. We report a series of studies conducted to determine the vaporisation efficiency of high doses of CBD, alone and in combination with ∆9-tetrahydrocannabinol (THC), to achieve faster onset effects in experimental and clinical [...]
Lire la suiteCommentaires (Dr Christian Sueur) sur l'article : The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI) : a multicentre case-control study Marta Di Forti, et al., and the EU-GEI WP2 Group* www.thelancet.com/psychiatry, 2019 "Une nouvelle étude montre que les personnes qui consomment quotidiennement du cannabis fortement dosé en THC pourraient avoir cinq fois plus de risque de faire un épisode de psychose que celles qui n’en ont jamais pris. La consommation quotidienne de variétés fortes de cannabis serait responsable de cinq nouveaux cas de troubles mentaux sur dix, de type psychose, à Amsterdam et de trois [...]
Lire la suiteDemystifying Cannabis Daniele Piomelli, Cannabis and Cannabinoid Research, Volume 4, Number 1, 2019 Mary Ann Liebert, Inc. DOI: 10.1089/can.2019.29012.edi Every new book by Malcolm Gladwell goes, by default, straight to the top of my reading list. In the unlikely event that you are not familiar with the work of this Canadian author, make time to read The Tipping Point (Little, Brown and Co., 2000) or Outliers (Little, Brown and Co., 2008), and you will see why. Not only Gladwell is remarkably well informed and clear, as one would expect from an accomplished writer and public speaker, but he also has an unusual knack for uncovering [...]
Lire la suiteCannabis and anxiety: a critical review of the evidence José Alexandre Crippa, Antonio Waldo Zuardi, Rocio Martin-Santos, Sagnik Bhattacharyya, Zerrin Atakan, Philip McGuire and Paolo Fusar-Poli Human Psychopharmacology Clinical and Experimental, 2009, 24, 515-523. Background : Anxiety reactions and panic attacks are the acute symptoms most frequently associated with cannabis use. Understanding the relationship between cannabis and anxiety may clarify the mechanism of action of cannabis and the pathophysiology of anxiety. Aims of the present study were to review the nature of the relationship between cannabis use and anxiety, as well as the possible clinical, diagnostic and causal implications. Method : Systematic review of the [...]
Lire la suiteVariétés de Cannabis: Par Docteur Ethan Russo http://www.cannabis-med.org/index.php?tpl=faq&red=faqlist&id=172&lng=fr Les consommateurs de cannabis ont souvent indiqué que les différentes variétés de cannabis produisent des effets variables, que se soit concernant les effets psychoactifs ou les bénéfices thérapeutiques. Les variétés sont généralement désignées comme étant soit Sativa, soit Indica, soit hybrides. Or, ces noms, d’un point de vue commercial, prêtent à confusion. Pour cette raison, la communauté scientifique s’est concentrée sur le Tétrahydrocannabinol (THC) qu’elle considérait comme la principale variable et la seule d’importance. En parallèle, jusqu’à très récemment, les croisements sélectifs des variétés de cannabis, destiné à l’usage récréatif ou à l’usage thérapeutique, [...]
Lire la suiteCannabidiol attenuates deficits of visuospatial associative memory induced by D9tetrahydrocannabinol M. Jerry Wright Jr, Sophia A. Vandewater and Michael A. Taffe Committee on the Neurobiology of Addictive Disorders, The Scripps Research Institute, La Jolla, CA, USA British Journal of Pharmacology, 2013, 170, 1365–1373 BACKGROUND AND PURPOSE Recent human studies suggest that recreational cannabis strains that are relatively high in cannabidiol (CBD) content produce less cognitive impairment than do strains with negligible CBD and similar D9tetrahydrocannabinol (THC) content. Self-selection in such studies means it is impossible to rule out additional variables which may determine both cannabis strain selection and basal cognitive performance level. Controlled laboratory studies can [...]
Lire la suiteHow effective and safe is medical cannabis as a treatment of mental disorders ? A systematic review Eva Hoch,· Dominik Niemann, · Rupert von Keller, · Miriam Schneider, · Chris M. Friemel, · Ulrich W. Preuss ,·Alkomiet Hasan, · Oliver Pogarell European Archives of Psychiatry and Clinical Neuroscience, 2019 Doi.org/10.1007/s00406-019-00984-4 Abstract : We conducted a review of systematic reviews (SRs) and randomized-controlled trials (RCTs) to analyze efficacy and safety of cannabis-based medication in patients with mental disorders. Five data bases were systematically searched (2006—August 2018); 4 SRs (of 11 RCTs) and 14 RCTs (1629 participants) were included. Diagnoses were: dementia, cannabis and opioid dependence, psychoses/schizophrenia, general [...]
Lire la suiteCannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S. Beckley Foundation, 2017. https://beckleyfoundation.org/resource/cannabidiol-inhibits-thc-elicited-paranoid-symptoms-and-hippocampal-dependent-memory-impairment/ Abstract Community-based studies suggest that cannabis products that are high in delta9-tetrahydrocannabinol (THC) but low in cannabidiol (CBD) are particularly hazardous for mental health. Laboratory-based studies are ideal for clarifying this issue because THC and CBD can be administered in pure form, under controlled conditions. In a between-subjects design, we tested the hypothesis that pre-treatment with CBD inhibited THC-elicited psychosis and cognitive impairment. Healthy participants were [...]
Lire la suite